194 related articles for article (PubMed ID: 23762361)
1. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4.
Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L
PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361
[TBL] [Abstract][Full Text] [Related]
2. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
3. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling.
James RG; Davidson KC; Bosch KA; Biechele TL; Robin NC; Taylor RJ; Major MB; Camp ND; Fowler K; Martins TJ; Moon RT
PLoS One; 2012; 7(12):e50457. PubMed ID: 23227175
[TBL] [Abstract][Full Text] [Related]
4. Development and structural analysis of adenosine site binding tankyrase inhibitors.
Haikarainen T; Waaler J; Ignatev A; Nkizinkiko Y; Venkannagari H; Obaji E; Krauss S; Lehtiö L
Bioorg Med Chem Lett; 2016 Jan; 26(2):328-333. PubMed ID: 26706174
[TBL] [Abstract][Full Text] [Related]
5. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
6. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.
Karlberg T; Markova N; Johansson I; Hammarström M; Schütz P; Weigelt J; Schüler H
J Med Chem; 2010 Jul; 53(14):5352-5. PubMed ID: 20565110
[TBL] [Abstract][Full Text] [Related]
10. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
11. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
12. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
[TBL] [Abstract][Full Text] [Related]
16.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
17. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
19. Zinc binding catalytic domain of human tankyrase 1.
Lehtiö L; Collins R; van den Berg S; Johansson A; Dahlgren LG; Hammarström M; Helleday T; Holmberg-Schiavone L; Karlberg T; Weigelt J
J Mol Biol; 2008 May; 379(1):136-45. PubMed ID: 18436240
[TBL] [Abstract][Full Text] [Related]
20. Regulation of tankyrase activity by a catalytic domain dimer interface.
Fan C; Yarravarapu N; Chen H; Kulak O; Dasari P; Herbert J; Yamaguchi K; Lum L; Zhang X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1780-1785. PubMed ID: 30055800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
